20 results
8-K
EX-99.1
IOBT
IO Biotech Inc
8 Jan 24
Regulation FD Disclosure
8:11am
to personalized approaches T-win® cancer vaccine technology platform with a dual mechanism of action Targets both the tumor and the immuno- suppressive … ).
IA 3Q-2024 Product candidates Line of therapy/ indication Pre-clinical Phase 1 Phase 2 Phase 3 Takeaways IO102-IO103 Targets: IDO, PD-L1 First Line
8-K
EX-99.2
18ck3hcsfhzjf3wqeul
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
DEF 14A
tushp39hjvjusu2cp6
14 Apr 22
Definitive proxy
4:02pm
10-K
s6qrel21
31 Mar 22
Annual report
5:07pm
10-Q
qirkf2hvryd93ip zjtf
17 Dec 21
Quarterly report
4:55pm
424B4
3rbwhs jq
8 Nov 21
Prospectus supplement with pricing info
5:20pm
S-1/A
EX-10.16
nmi4e0wtj9
26 Oct 21
IPO registration (amended)
5:15pm
S-1
mh136 1sv97
15 Oct 21
IPO registration
5:18pm
DRS/A
nyy7 pcqtavg
6 Oct 21
Draft registration statement (amended)
12:00am
DRS/A
fdq7qj6
9 Aug 21
Draft registration statement (amended)
12:00am
DRS
j64 i6t5c74
3 Jun 21
Draft registration statement
12:00am
- Prev
- 1
- Next